The Arizona Controlled Substances Prescription Monitoring Program (“PMP”) was established in 2007 and provides the State of Arizona with a central database to track the dispensing of controlled substances. The PMP is designed to assist providers in making better-informed decisions and help “prevent the diversion and misuse of controlled substances at the provider, pharmacy, and…
The Best Lawyers in America© is the longest-running peer-review publication in the legal profession.
We are pleased to announce today that Chambers USA ranked Milligan Lawless, P.C. and 4 of our attorneys among the best in Arizona for 2024. Among Arizona law firms, Milligan Lawless achieved a Band 1 ranking, Chambers USA’s highest recognition, in the Healthcare practice area. Chambers USA is an annual ranking that assesses each law…
The Best Lawyers in America© is the longest-running peer-review publication in the legal profession.
The Medication Access and Training Expansion (“MATE”) Act was signed into law on December 29, 2022. The Act applies to all “qualified practitioners” anticipating initial or renewal DEA registration on or after June 27, 2023. A qualified practitioner is someone licensed under state law to prescribe controlled substances (excluding veterinarians). As part of the DEA…
We are pleased to announce today that Chambers USA ranked Milligan Lawless, P.C. and 4 of our attorneys among the best in Arizona for 2023. Among Arizona law firms, Milligan Lawless achieved a Band 1 ranking, Chambers USA’s highest recognition, in the Healthcare practice area. Chambers USA is an annual ranking that assesses each law…
The materials provided in this website are for informational purposes only and are not for the purpose of providing legal advice. Transmission of information from the ML website is not intended to create, and its receipt by you does not create an attorney-client relationship with ML or any of its individual attorneys or personnel.
If you elect to communicate with anyone at ML through this website, or otherwise, in connection with a matter for which we do not already represent you, your communication can not be treated as privileged or confidential. Do not transmit any information about any matter (and particularly not information you regard as confidential) that may involve you until ML has agreed to represent you, and you have received confirmation of that fact in the form of a written engagement letter.